Navigation Links
Max Neeman International Expands Upon Cardiology and Device Trial Experience to Meet Increased Medical Device Development in India
Date:9/13/2010

RESEARCH TRIANGLE PARK, N.C., Sept. 13 /PRNewswire/ -- Max Neeman International, a leading Indian CRO, announces the expansion of therapeutic focused device clinical trial services in India. Max Neeman has formed an experienced and world class team of medical device experts specializing in carrying out cardiac device trials – therapeutic, diagnostic and surgical. Coronary artherectomy, cardiac stents, aneurysm, mitral valve regurgitation and acute coronary syndrome form 90% of the total device trial experience. These are multicentric global trials with patients as high as 300.  Along with prior experience of conducting device trials, the specialized Max Neeman team and services adds an enhanced level of company expertise in conducting simple to complex device studies.  Max Neeman also has medical device operations and regulatory experience in various other device therapeutic areas as well including CNS and Ophthalmology.

India is emerging as a destination of choice for medical device development and conducting device trials as the market for percutaneous coronary interventions has expanded.  India's device market is currently valued at US $1.7 Billion and projected to grow at the rate of 23% annually.  Benefits which have accelerated outsourcing of device trials to India include: shortened product development cycle, faster time to market (by approximately 30% due to faster patient recruitment) and testing resulting in significant cost savings of about 40-50%.  Max Neeman International conducts device studies for small to large device firms across the globe delivering high quality results at a lower cost resulting in high client satisfaction.  

About Max Neeman International
Max Neeman International is one of the leading and largest CROs in India. Our specialty is that we offer services for the successful conduct of Phase I-IV clinical and device trials for small and mid-sized international and national Pharmaceutical, Biotechnology, Medical Device and Nutraceutical companies in compliance with ICH GCP standards. Operational since 2001, Max Neeman is an ISO 9001:2008 certified CRO for Monitoring, Site Management and Data Management Services. The company is presently active in over 22 cities with 6 regional offices.  Contact Donald Swankie, Vice President of Business Development via email to donald.swankie@neeman-medical.com or call +1.919.424.3345.  For more information please visit www.neeman-medical.com.


'/>"/>
SOURCE Max Neeman International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Max Neeman International Expands Data Management Services with Conversion Into CDISC Standard Data Model
2. Max Neeman International and AMEDON Collaborate to Increase EDC Performance
3. Max Neeman International Expands Specialized Surgical Team for Clinical Trials
4. PRA Internationals Drug Safety Experts to Speak at Safety Congress
5. Biosystems International Merges With Microbiochips
6. Medizone International Files For Additional Bio-Terrorism Countermeasures Patent Protection
7. International Isotopes Inc. Announces Completion of a Licensing and Permitting Assistance Agreement with URENCO USA
8. Dyadic International and EnGen Bio to Present at Rodman & Renshaw Annual Global Investment Conference
9. Dyadic International Raises Additional $1 Million to Complete $4 Million Convertible Note Offering
10. /C O R R E C T I O N - Mindray Medical International Limited /
11. Ellman International Announces Executive Team Hire
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ANN ARBOR, Mich. , Feb. 8, 2016 /PRNewswire-USNewswire/ ... Ann Arbor announced today that, as part ... will become one of the first hospitals in the ... Karin Muraszko , M.D., U-M,s chair of ... U-M,s chair of neurosurgery. --> The ...
(Date:2/8/2016)... 2016 Velano Vascular, a medical technology company ... and their practitioners, announced today that the company has ... use the proceeds from this financing, an extension of ... 2015, to support the development and commercialization of the ... Philadelphia , and a ...
(Date:2/8/2016)... 2016  HemaFlo Therapeutics, Inc. announced today that the United ... Number 9,119,880 covering the use of NephroFlow to treat acute ... HemaFlo,s founder, said, "We are pleased to secure our rights ... Peterson , PhD, HemaFlo,s founder, said, "We are pleased to ... --> Dale Peterson , PhD, HemaFlo,s founder, said, ...
Breaking Medicine Technology:
(Date:2/8/2016)... SC (PRWEB) , ... February 08, 2016 , ... Steve ... areas with a vital new community enrichment program, has teamed up with Citizens Opposed ... and children suffering from intimate abuse. To support all those victimized by the fear ...
(Date:2/8/2016)... ... ... Remember the old saying “rub some dirt on it”? Perhaps you should ... Bentonite Clay” the health benefits of integrating clay into a daily diet are numerous, ... former motivational speaker, Perry A~ has since dedicated her life to learning about the ...
(Date:2/8/2016)... ... February 08, 2016 , ... The ... important news! AHCC and the Home Health and Hospice ICD-10 Transition Workgroup are ... official ICD coding guidance and clarifications, to address concerns over the use of ...
(Date:2/8/2016)... ... 2016 , ... According to research by the National Association ... to be certified or obtain continuing education. To increase patient awareness of the ... Mouth?” campaign to inform dentists and patients about the possible lack of skills ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , This ... an estimated 5000 perioperative nurses in attendance to study the latest evidence-based ...
Breaking Medicine News(10 mins):